Company: LENZ
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001815776-25-000071
Chunk: 272

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 272
---
Item 1. Financial Statements.

LENZ THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except for shares and par value)

September 30, 2025December 31, 2024(unaudited)AssetsCurrent assets:Cash and cash equivalents$25,399 $20,158 Marketable securities176,773 188,872 Inventory949 — Prepaid expenses and other current assets3,876 2,773 Restricted cash— 114 Total current assets206,997 211,917 Property and equipment, net1,258 651 Operating lease right-of-use asset847 1,338 Other assets1,602 1,398 Total assets$210,704 $215,304 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable$4,323 $4,257 Accrued liabilities11,993 6,149 Total current liabilities16,316 10,406 Operating lease liability, net461 814 Total liabilities16,777 11,220 Commitments and contingencies (Note 6)Stockholders' equity:Common stock, par value of $0.00001 per share; 300,000,000 shares authorized; 28,588,261 and 27,531,490 shares issued at September 30, 2025 and December 31, 2024, respectively; and 28,588,261 and 27,518,439 shares outstanding at September 30, 2025 and December 31, 2024, respectively1 1 Additional paid-in capital384,944 348,901 Accumulated deficit(191,245)(145,014)Accumulated other comprehensive income227 196 Total stockholders’ equity193,927 204,084 Total liabilities and stockholders’ equity$210,704 $215,304 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

1

Table of Contents

LENZ THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share data)

(unaudited)

Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Revenue:License revenue$12,500 $— $17,500 $—